SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its drug Tinlarebant, aimed at treating Stargardt disease (STGD1). This designation is based on interim results from the Phase 3 DRAGON trial, showcasing Tinlarebant's efficacy and safety. Notably, there are currently no approved treatments for STGD1. This grant marks a significant step forward in addressing the serious unmet needs of the Stargardt community. Trial completion is expected by Q4 2025. Belite Bio has previously received multiple designations for Tinlarebant, including Fast Track and Rare Pediatric Disease Designations in the U.S., and Orphan Drug Designation in the U.S., Europe, and Japan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.